tapebrief

ZTS · Q2 2025 Earnings

Bullish

Zoetis

Reported August 5, 2025

30-second summary

30-second take: Zoetis delivered 8% organic operational revenue growth and 10% organic operational adjusted net income growth in Q2, enough to raise full-year guidance on both revenue (now 6.5–8.0%) and adjusted net income (now 5.5–7.5%). The standout was livestock at +6% organic operational in Q2 and +7% YTD against low-single-digit market growth — a fifth straight quarter above 5%. The friction point is Librela: U.S. patient starts are going backwards (U.S. -16%, international +1%, global -7%), management is reframing it as a "deliberate market development" phase, and the third-party safety studies that vets are asking for don't read out until Q4 2025.

Headline numbers

EPS

Q2 FY2025

$1.76

Revenue

Q2 FY2025

$2.46B

+4.2% YoY

Gross margin

Q2 FY2025

73.6%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$2.46B+4.2%
EPS$1.76
Gross margin73.6%

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
U.S. Segment$1.356B+4.0%
International Segment$1.07B+3.4%
Companion Animal$1.788B+8.4%
Livestock$0.638B-8.1%
Dogs and Cats$1.716B+8.5%
Cattle$0.32B-8.6%
Swine$0.119B-8.5%
U.S. Companion Animal Growth9%
U.S. Livestock Organic Operational Growth-2%
International Companion Animal Growth8%
International Livestock Organic Operational Growth10%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Brazil$0.093B-5.6%
Organic Operational Revenue Growth8%
Organic Operational Adjusted Net Income Growth10%
Adjusted Gross Margin73.7%
Full Year 2025 Adjusted EPS Guidance$6.30 to $6.40

Management tone

Management raised guidance while simultaneously conceding more product-specific friction than is typical for a guide-up quarter — a more candid posture than the format usually elicits.

The most consequential shift is on Librela. Management moved from positioning it as a breakthrough innovation with confident adoption to acknowledging declining patient starts in the U.S. and reframing the stall as a "deliberate market development phase." Librela declined 7% operationally globally, with U.S. -16% on $45M and international +1% on $64M — so the issue is acute in the U.S. and present-but-milder in English-speaking international markets where social media headlines have bled over. From the call: "As with any breakthrough innovation that establishes a new standard of care, adoption rarely follows a straight line. That's why we're taking deliberate steps to develop the market, educating veterinarians and pet owners." The signal: the third-party safety studies vets are asking for don't read out until Q4 2025 into 2026, so the "trust gap" persists through year-end at minimum.

Livestock has shifted from a low-expectations stable contributor to a structural outperformer. Management called out the fifth consecutive quarter of organic operational growth above 5%, with Q2 at +6% and YTD at +7% against low-single-digit market growth projections. This is now being framed as durable rather than a comp-driven beat.

Alternative channels graduated in the narrative from "emerging diversification" to a structural compliance and stickiness advantage, with retail channel sales more than doubling. Management is positioning this as a moat, not an experiment.

On Simparica, the framing shifted from defense against Quattro's entry to category expansion: zero patient share loss since competition launched ~two years ago, with triple-combination penetration in vet practices expanding from 30% to 45%. Management explicitly downplayed Quattro's impact as "relatively small."

Recurring themes management leaned on this quarter:

Innovation as core competitive moat and purpose driverPortfolio diversification across species, geographies, and channels delivering broad-based growthMarket expansion opportunity with significant addressable patient populations remaining undertreated globallyAlternative channel strategy as structural differentiation and compliance driverLivestock outperformance and sustained momentum above market growthDeliberate market development approach for breakthrough innovations requiring adoption education

Risks management surfaced:

Labrella adoption headwinds from perceived safety concerns and social media headlines impacting new patient startsCompetitive pressures in Semperica and Key Dermatology franchises launching in second halfTariff impacts and policy uncertainties with incremental impact requiring absorptionMacro environment uncertainty affecting customer spendingSupply timing impacts on specific products like Sestafia fear

Q&A highlights

Michael Ryskin · Bank of America

Asked about go-to-market strategy changes for TRIO/Durham franchises amid increased competition, pricing pressure, and retail channel leverage. Also inquired on Librella timing for return to growth and when medical education/studies will drive benefits.

Management stated no changes to go-to-market strategy, disciplined promotion approach, better price realization, and zero patient share loss since competition arrived. TRIO grew 20% (19% US), Semperica 18%. For Librella, emphasized 75%+ satisfaction rate, third-party studies reading out Q4 2024-2025, vet education focus, and confident in long-term potential without committing to specific return-to-growth timeline.

TRIO grew 20% overall, 19% in USSemperica franchise grew 18% in quarter, 25% last yearTriple combination market segment grew 45% last yearTRIO is leading product in flea/tick/heartworm combination

Brandon Vasquez · William Blair

Followed up on Librella slowdown despite positive clinical data and RCT results. Asked what vets want to see to reaccelerate usage and requested granular pipeline/lifecycle innovation details for 12-18 month outlook.

Management acknowledged Librella performance is lagging expectations and vets are requesting better data to drive recommendations. Emphasized third-party studies as solution to empower vets. On pipeline, stated major approvals expected every year for next few years: long-acting OA pain (dog/cat this year), long-acting Cytopoint, and renal product (in 12-36 month window). Noted renal is $3-4B market, oncology >$1.5B, cardiology significant.

Librella performance lagging expectations with headwinds impacting patient adoptionVets requesting better data to support recommendationsThird-party studies underway for clinical validationMajor approval expected every year for next few years

Erin Wright · Morgan Stanley

Asked about ability to achieve high single-digit to mid-60s% operational growth next year amid competitive landscape and pipeline innovation. Also inquired on operating margin progression drivers and any timing benefits.

Management emphasized broad-based results driven by portfolio innovation and execution excellence. Highlighted diversity across markets/species and expectation of major market approval every year for next few years. On margins, noted gross margins largely as expected, manufacturing costs elevated due to inventory built last year improving in H2, 10% adjusted net income growth in Q2, continued cost discipline, and share buybacks contribution at EPS level. Noted strong prior-year comps (companion animal +15% Q3 2024, +18% US).

10% adjusted net income growth in Q2Gross margins marginally favorable to plan in Q2Manufacturing costs elevated from last-year inventory build, improving in H2Q3 2024 comparisons: companion animal +15%, US +18%

David Westenberg · Piper Sandler

Asked about strategies to leverage Cytopoint (injectable) to maintain dermatology market share amid oral competition, growth rate vs. orals, and slowdown in biologics category. Also requested clarification on contract manufacturing human health step-up.

Management highlighted three differentiated offerings in dermatology: Apoquel (10+ years safety/efficacy), chewable formulation, and Cytopoint (preferred for many vets, long-acting relief, eliminates compliance issues). Investing in long-acting Cytopoint pipeline (approval expected 12-36 months). Underscored 20 million under-treated/untreated medicalized dogs, market expansion focus, and Durham growing 17% last year with double-digit volume growth. On contract manufacturing, stated it remains small, moved higher as percentage but nothing specific to note.

Durham grew 17% last year with double-digit volume growth20 million medicalized dogs are either under-treated or untreatedLong-acting Cytopoint approval expected 12-36 monthsCytopoint preferred solution for many vets

Chris Schott · J.P. Morgan

Asked about parasiticide market trajectory and penetration, specifically what inning of transition to triple combinations and competitive impact from Quattro.

Management stated triple combinations expected to double by end of 2028, with 45% market share in vet practices for triples. Noted 60% of puppies immediately prescribed triple combinations. Regarding Quattro competitive entry, impact has been relatively small given high growth in segment; more entrants will drive awareness/advertising that benefits overall market and Zoetis position with established 5-year track record and high customer satisfaction.

45% share in vet practices for triple combinationsTriple combinations expected to double by end of 202860% of puppies immediately started on triple combinationsQuattro impact has been relatively small

What to watch into next quarter

Librela patient starts trajectory in Q3 — management has staked the recovery thesis on third-party studies reading out Q4 2025 into 2026, so Q3 should show whether the U.S. bleed has stabilized or worsened ahead of any data catalyst.

U.S. Livestock organic operational growth — Q2 came in at -2% against International Livestock at +10%; watch whether U.S. inflects positively or the divergence widens.

Simparica franchise growth rate — global franchise grew 17% in Q2 vs. +25% for full-year 2024 (first full year post-competition). Watch whether the rate holds in the mid- to high-teens as Quattro builds awareness, even if patient share holds.

Adjusted gross margin in H2 — management flagged manufacturing cost headwinds from prior-year inventory build "improving in H2." Q2 came in at 73.7%; watch for sequential expansion that validates the framing.

2026 framing on the Q3 or Q4 call — management deflected 2026 questions citing it being early; first concrete signal on whether the raised 6.5–8% organic operational revenue algorithm extends into next year is the next major datapoint.

Sources

  1. Zoetis Q2 2025 earnings press release (SEC EDGAR filing, exhibit99q22025.htm)
  2. Zoetis Q2 2025 earnings call prepared remarks and Q&A

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.